Abstract: The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.

Abstract: An exercise device and associated methods that in configurable in either a glider mode or a balance mode. The device includes: a footbed having a toe separator, a chassis having a first surface mated to the footbed and a second opposed surface having a plurality of attachment points; a strap configured to secure a foot onto the footbed; and at least one balance dome releasably attachable to a selected attachment point.

Abstract: The present disclosure provides, among other things, a vaccine composition that includes a squalene nanoemulsion (SNE) adjuvant and HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Abstract: The invention relates to novel compounds and formulations. Further, the invention relates to novel compounds and formulations useful in pneumococcal and pneumococcal conjugate vaccines. More specifically, the invention relates to compositions comprising pneumococcal conjugates and one or more compounds of Formula I, Ia, II, IIa, III, IIIa, IV, or IVa, or a pharmaceutically acceptable salt thereof, prepared as stable nanoemulsions (herein referred to as “SNE adjuvant compositions” or “SNEs”).

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Abstract: The present invention relates generally to the prevention of pneumococcal disease. More specifically, the invention relates to compositions comprising pneumococcal conjugates and a lipid nanoparticle (LNP).

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Abstract: The present invention relates generally to the prevention of pneumococcal disease. More specifically, the invention relates to a composition comprising pneumococcal conjugates and a stable nanoemulsion (SNE).

Abstract: A novel configuration for an axial flow gas turbine engine for aircraft has an engine core having a core length and including a first turbine, an axial compressor, and a drive connecting the first turbine to the axial compressor, the engine core further including a second turbine, and a fan shaft connecting the second turbine to a fan located upstream of the engine core, the fan including a plurality of fan blades extending from a fan hub, the fan having a tip radius from 90 mm to 225 mm and wherein the ratio of fan tip radius to an engine length is 0.15 to 0.25. The engine may have 3, 4 or 5 compressor stages and combustor volume (in litres) which when divided by fan tip radius (in mm) is 0.015 to 0.083. The fan may be multistage fan configured to permit an electric motor to be located within fan hub diameter.

Abstract: An apparatus, system and technique selectively eliminates the noxious signal components in a neuronal signal by creating an interfering electrical signal that is tuned to a given frequency corresponding to the oscillatory pattern of the noxious signal, resulting in a modified neuronal signal that substantially reproduces a normal, no-pain neuronal signal. The disclosed system and technique of pain relief is based on the hypothesis that the temporal profile of pain signals encodes particular components that oscillate at unique and quantifiable frequencies, which are responsible for pain processing in the brain.

Abstract: An apparatus, system and technique selectively eliminates the noxious signal components in a neuronal signal by creating an interfering electrical signal that is tuned to a given frequency corresponding to the oscillatory pattern of the noxious signal, resulting in a modified neuronal signal that substantially reproduces a normal, no-pain neuronal signal. The disclosed system and technique of pain relief is based on the hypothesis that the temporal profile of pain signals encodes particular components that oscillate at unique and quantifiable frequencies, which are responsible for pain processing in the brain.

Abstract: A novel configuration for an axial flow gas turbine engine for an aircraft has an engine core having a core length and including a first turbine, an axial compressor, and a drive connecting the first turbine to the axial compressor, the engine core further including a second turbine, and a fan shaft connecting the second turbine to a fan located upstream of engine core, the fan including a plurality of fan blades extending from a fan hub, the fan having a tip radius from 90 mm to 225 mm and wherein the ratio of fan tip radius to engine length is 0.15 to 0.25. The engine may have 3, 4 or 5 compressor stages and a combustor volume (in litres) which when divided by the fan tip radius (in mm) is 0.015 to 0.083. The fan may be multistage fan configured to permit electric motor to be located within fan hub diameter.

Abstract: A novel configuration for axial flow gas turbine engine for aircraft has an engine core having a core length and including first turbine, axial compressor, and drive connecting the first turbine to the axial compressor, the engine core further including a second turbine, and a fan shaft connecting the second turbine to a fan located upstream of the engine core, the fan including a plurality of fan blades extending from a fan hub, the fan having a tip radius from 90 mm to 225 mm and wherein the ratio of fan tip radius to an engine length is 0.15 to 0.25. The engine may have 3, 4 or 5 compressor stages and a combustor volume (in litres) which when divided by the fan tip radius (in mm) is 0.015 to 0.083. The fan may be a multistage fan configured to permit an electric motor to be located within the fan hub diameter.

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.

Abstract: The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.

Abstract: An apparatus, system and technique selectively eliminates the noxious signal components in a neuronal signal by creating an interfering electrical signal that is tuned to a given frequency corresponding to the oscillatory pattern of the noxious signal, resulting in a modified neuronal signal that substantially reproduces a normal, no-pain neuronal signal. The disclosed system and technique of pain relief is based on the hypothesis that the temporal profile of pain signals encodes particular components that oscillate at unique and quantifiable frequencies, which are responsible for pain processing in the brain.

Abstract: The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.

Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which polysaccharides obtained from bacterial capsules are conjugated to diphtheria toxin fragment B (DTFB) or a variant thereof. The immunogenic compositions may be multivalent pneumococcal polysaccharide conjugate compositions in which polysaccharides from one or more Steptococcus pneumoniae serotypes are conjugated to diphtheria toxin fragment B (DTFB) and, optionally, additional polysaccharides from one or more different Steptococcus pneumoniae serotypes are conjugated to one or more other carrier proteins.

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.